Latest Ratios: P/E Ratio -4.5x · EV/EBITDA 24.1x · ROE -25.6%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $427M | $263M | $606M | $803M | $997M | $1.0B | $320M | $416M | $261M | $461M | $566M |
| Enterprise Value | $321M | $156M | $528M | $791M | $1.2B | $1.2B | $397M | $510M | $329M | $535M | $632M |
| P/E Ratio → | -4.51 | — | — | 11.04 | 5.29 | 7.86 | — | — | — | 12.63 | 104.07 |
| P/S Ratio | 0.41 | 0.25 | 0.45 | 0.40 | 0.36 | 0.62 | 0.38 | 0.51 | 0.32 | 0.53 | 0.68 |
| P/B Ratio | 1.33 | 0.81 | 1.45 | 1.70 | 2.18 | 3.49 | 2.07 | 2.55 | 1.20 | 1.94 | 3.73 |
| P/FCF | 10.66 | 6.55 | 5.44 | 3.42 | 7.96 | — | 14.17 | 159.94 | 15.94 | 11.42 | 23.95 |
| P/OCF | 8.86 | 5.44 | 5.05 | 3.23 | 7.44 | — | 11.77 | 75.09 | 12.45 | 10.14 | 18.77 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.15 | 0.39 | 0.39 | 0.41 | 0.74 | 0.47 | 0.62 | 0.40 | 0.62 | 0.76 |
| EV / EBITDA | 24.08 | 11.71 | 832.13 | 6.04 | 4.08 | 8.29 | 964.73 | — | — | 24.41 | 41.14 |
| EV / EBIT | — | — | — | 7.13 | 4.30 | 8.49 | 24.30 | 57.52 | — | 62.84 | 19.67 |
| EV / FCF | — | 3.89 | 4.74 | 3.37 | 9.19 | — | 17.55 | 196.03 | 20.03 | 13.25 | 26.76 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.7% | 18.7% | 20.4% | 22.3% | 22.3% | 22.4% | 24.2% | 24.8% | 25.7% | 26.4% | 26.6% |
| Operating Margin | -0.3% | -0.3% | -1.3% | 5.6% | 9.6% | 8.3% | -1.1% | -1.9% | -1.6% | 1.4% | 0.7% |
| Net Profit Margin | -9.0% | -9.0% | -1.1% | 3.6% | 6.6% | 7.9% | -1.5% | -7.0% | -2.1% | 4.3% | 1.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.6% | -25.6% | -3.3% | 15.6% | 49.3% | 58.4% | -8.1% | -30.2% | -7.4% | 19.3% | 5.4% |
| ROA | -18.3% | -18.3% | -2.3% | 8.9% | 22.1% | 24.2% | -3.5% | -14.3% | -3.8% | 8.8% | 2.1% |
| ROIC | -0.9% | -0.9% | -3.2% | 15.8% | 36.7% | 28.9% | -2.8% | -4.3% | -3.2% | 3.3% | 2.1% |
| ROCE | -0.8% | -0.8% | -3.4% | 18.7% | 44.6% | 35.0% | -3.3% | -4.9% | -3.6% | 3.5% | 2.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.35 | 0.66 | 0.50 | 0.58 | 0.38 | 0.42 | 0.57 |
| Debt / EBITDA | 0.17 | 0.17 | 6.10 | 0.04 | 0.56 | 1.31 | 189.79 | — | — | 4.52 | 5.66 |
| Net Debt / Equity | — | -0.33 | -0.19 | -0.02 | 0.34 | 0.65 | 0.49 | 0.57 | 0.31 | 0.31 | 0.44 |
| Net Debt / EBITDA | -7.98 | -7.98 | -122.46 | -0.09 | 0.55 | 1.31 | 185.89 | — | — | 3.36 | 4.32 |
| Debt / FCF | — | -2.65 | -0.70 | -0.05 | 1.23 | — | 3.38 | 36.08 | 4.10 | 1.82 | 2.81 |
| Interest Coverage | -1.56 | -1.56 | -0.33 | 13.71 | 18.59 | 21.13 | 5.65 | 1.67 | -2.22 | 2.02 | 5.26 |
Net cash position: cash ($109M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.78 | 3.78 | 2.78 | 2.79 | 2.49 | 2.54 | 1.96 | 2.15 | 2.28 | 2.21 | 2.12 |
| Quick Ratio | 3.78 | 3.78 | 2.78 | 2.79 | 2.45 | 2.54 | 1.96 | 2.15 | 2.21 | 2.15 | 2.05 |
| Cash Ratio | 1.40 | 1.40 | 0.68 | 0.12 | 0.01 | 0.01 | 0.02 | 0.01 | 0.19 | 0.27 | 0.21 |
| Asset Turnover | — | 2.35 | 2.28 | 2.97 | 2.96 | 2.29 | 2.34 | 2.15 | 1.91 | 1.85 | 2.15 |
| Inventory Turnover | — | — | — | — | 196.88 | — | — | — | 97.76 | 120.38 | 99.87 |
| Days Sales Outstanding | — | 57.99 | 65.96 | 70.18 | 85.93 | 108.62 | 76.24 | 77.48 | 76.14 | 74.73 | 77.36 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 9.1% | 18.9% | 12.7% | — | — | — | 7.9% | 1.0% |
| FCF Yield | 9.4% | 15.3% | 18.4% | 29.2% | 12.6% | — | 7.1% | 0.6% | 6.3% | 8.8% | 4.2% |
| Buyback Yield | 1.6% | 2.6% | 6.2% | 7.2% | 3.5% | 0.2% | 0.2% | 0.2% | 1.9% | 0.4% | 0.0% |
| Total Shareholder Yield | 1.6% | 2.6% | 6.2% | 7.2% | 3.5% | 0.2% | 0.2% | 0.2% | 1.9% | 0.4% | 0.0% |
| Shares Outstanding | — | $32M | $33M | $35M | $38M | $37M | $36M | $36M | $36M | $36M | $36M |
Structural Revenue Normalization
Based on recent financial filings, CCRN's forward P/E of 142.92 suggests that the market is pricing in a significant earnings recovery, even as the current TTM P/E of -4.51 reflects the immediate impact of negative net margins during this period of industry-wide revenue contraction.
The extreme forward multiple indicates that investors are looking past current losses toward a potential normalization of profitability. However, the P/S ratio of 0.41 suggests that the market remains skeptical of the company's ability to regain its previous scale, warranting caution regarding the sustainability of current valuation levels.
As reported in financial statements, CCRN's gross margin has compressed to 18.2% in 2026Q1, which, when combined with a negative operating margin of -0.8%, highlights the difficulty in maintaining profitability as the bill-pay spread narrows in a post-pandemic healthcare labor market.
The inability to maintain positive operating margins suggests that fixed costs remain misaligned with the current revenue environment. Investors should monitor whether management can successfully right-size the SG&A structure to restore positive net margins without sacrificing the MSP infrastructure that supports long-term client retention.
According to recent quarterly data, CCRN's ROIC has fallen to -0.7% in 2026Q1, a stark reversal from the positive returns observed in 2024, indicating that the company is currently failing to generate value from its invested capital during this cyclical downturn.
The decline in ROIC is primarily driven by the erosion of net margins rather than asset turnover, which has remained relatively stable. This trend suggests that the company's capital allocation strategy is currently hindered by the broader industry contraction, making it difficult to achieve historical compounding rates.
Based on reported figures, CCRN's DSO has fluctuated between 66 and 91 days over the last ten quarters, serving as a vital indicator of the company's ability to collect from hospital clients during periods of significant revenue volatility and industry-wide financial stress.
The variability in DSO suggests that payment cycles remain sensitive to the financial health of hospital systems, which are currently managing their own margin pressures. Maintaining efficient collection cycles is essential for CCRN to preserve its liquidity position while the core staffing business undergoes a structural correction.
Investors frequently misapply the P/E ratio to CCRN, which obscures the company's underlying cash-generating capacity during cyclical downturns when non-cash charges like goodwill impairments disproportionately depress reported net income and create misleadingly negative or volatile earnings multiples.
Given the company's tendency to generate positive free cash flow even during periods of net losses, the P/FCF ratio is a more reliable metric for assessing valuation. Relying on P/E in this context may lead to an overly pessimistic assessment of the company's intrinsic value and recovery potential.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CCRN stock.
Cross Country Healthcare, Inc.'s current P/E ratio is -4.5x. The historical average is 39.2x.
Cross Country Healthcare, Inc.'s current EV/EBITDA is 24.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.0x.
Cross Country Healthcare, Inc.'s return on equity (ROE) is -25.6%. The historical average is 1.3%.
Based on historical data, Cross Country Healthcare, Inc. is trading at a P/E of -4.5x. Compare with industry peers and growth rates for a complete picture.
Cross Country Healthcare, Inc. has 18.7% gross margin and -0.3% operating margin.
Cross Country Healthcare, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.